Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-05-20
2009-02-24
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263220, C514S263230, C514S263340, C514S263350, C514S263300, C544S267000, C544S269000, C544S272000
Reexamination Certificate
active
07495004
ABSTRACT:
The invention relates to methods for the treatment or prevention of an LXR mediated disease or condition, including cardiovascular disease and atherosclerosis, novel compounds of formula (I) for use in such methods and pharmaceutical compositions comprising compounds for use in such methods.
REFERENCES:
patent: 2928833 (1960-03-01), Leake et al.
patent: 4883801 (1989-11-01), Nathanson
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 5102880 (1992-04-01), Chakravarty et al.
patent: 5157026 (1992-10-01), Chakravarty et al.
patent: 5177074 (1993-01-01), Allen et al.
patent: 5332744 (1994-07-01), Chakravarty et al.
patent: 5374638 (1994-12-01), Dhanoa et al.
patent: 5409934 (1995-04-01), Smith et al.
patent: 5412097 (1995-05-01), Chakravarty et al.
patent: 5461059 (1995-10-01), Bonnet et al.
patent: 5470579 (1995-11-01), Bonte et al.
patent: 5641784 (1997-06-01), Kufner-Muhl et al.
patent: 5714494 (1998-02-01), Connell et al.
patent: 5719279 (1998-02-01), Kufner-Muhl et al.
patent: 6187780 (2001-02-01), Blech et al.
patent: 6316503 (2001-11-01), Hasegawa et al.
patent: 6821978 (2004-11-01), Chackalamannil et al.
patent: 7074923 (2006-07-01), Dahanukar et al.
patent: 7192952 (2007-03-01), Kanstrup et al.
patent: 2006/0205711 (2006-09-01), Himmelsbach et al.
patent: 2062558 (1992-03-01), None
patent: 4325254 (1994-02-01), None
patent: 400974 (1990-12-01), None
patent: 430300 (1991-06-01), None
patent: WO 92/05175 (1992-04-01), None
patent: WO 92/05176 (1992-04-01), None
patent: WO 92/11260 (1992-07-01), None
patent: WO 93/23401 (1993-11-01), None
patent: WO 94/03456 (1994-02-01), None
patent: WO 94/20460 (1994-09-01), None
patent: WO 99/36073 (1999-07-01), None
patent: WO 00/09507 (2000-02-01), None
patent: WO 00/54759 (2000-09-01), None
patent: WO 01/34610 (2001-05-01), None
patent: WO 01/60824 (2001-08-01), None
patent: WO 01/68600 (2001-09-01), None
patent: WO 02/02560 (2002-01-01), None
patent: WO 02/24632 (2002-03-01), None
patent: WO 02/24698 (2002-03-01), None
patent: WO 02/067942 (2002-09-01), None
patent: WO 02/068420 (2002-09-01), None
patent: WO 03/004496 (2003-01-01), None
Samura et al., Pharmaceutical Chemistry Journal vol. 20, No. 1 Jan. 1986 pp. 37-40.
Collins, J.L., et al. “Identification of a Nonsteroidal Liver X Receptor Agonist Through Parallel Array Synthesis of Tertiary Amines.” Journal of Medicinal Chemistry, American Chemical Society. Vo. 45, 2002, pp. 1963-1966.
Chlon, G et al.; Synthesis, 5-HT1A and 5-HT2A Receptor Activity of New 1-Phenylpiperazinylpropyl Derivatives with Arylakyl Substituents in Position 7 of Purine-2,6-Dione; Pol J Pharm: 2001; 53/4; 359-368; Polish Academy of Sciences, Institute of Pharmacology.
Pozharskii, AF, et al.; N-Anions of Heteroarymatic Amines,; Khlm Geterotslkt Soedln (Russian); 1971; 7/9; 1230-1237, abstract only.
Priimenko, BA et al.; Synthesis and Physicochemical Properties of 7,8-Disubstituted 3-Methylxanthine and 2,6,7,8-tetrasubstituted Purine; Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya; 1986; 29/2; 35-38; (Russian), Abstract only.
Romanenko, NI, et al.; Reactions of 7-Substituted 8-bromo-3-methylxanthine with some Electrophilic and Nucleophilic Reagents; Ukr. Khim. Zh. (Russian); 1987; 53/9; 983-986, Abstract only.
Romanenko, NI, et al.; Synthesis and Antibacterial and Antifungal Activity of Some 3-methyl-8-nitroxanthine Derivatives; Khimiko-Farmatsevticheskii Zhurnal; 1997; 31/4; 28-29, Abstract only.
Bolte, M. “Nearly Centrosymmetric (S)-7-(2,6-dichlorobenzyl)-8-(3-oxocyclopentyl)-1,3-dipropyl-7H-purine-2,6-dione.” Acta Cryst, Sect. C, 1996, C52(8), pp. 1985-1987.
Drabczynska, A., et al. “Structure and Activity Studies of Glycine Receptor Ligands. Part 4. N-[(7-arylalkyl,7-aryloxyalkyl)-8-theophyllyl]-glycines.” Pol. J. chem.., 1999, 73(5), pp. 783-792.
Drabczynska, A., et al. “Synthesis and preliminary Pharmacological Screening of Some 8-Substituted Methylxanthines.” Pol. J. Pharmacol. Pharm., 1989, 41(4), pp. 385-394.
Jarymowicz, B. “Pochodne 1,3-Dimetylo-8-Formylo-7-Podstawione Ksantyny W Syntezie Hantzscha.” ACTA Polon. Pharm. XXXVIII, No. 2, 1981, pp. 201-205.
Mosselhi, M.A.N., et al. “Synthesis and Properties of 8-nitro-7-alkylated Theophylline Derivatives.” Bull. Pol. Acad. Sci., Chem., 1994, 41(30, pp. 179-185.
Mosselhi, M.A.N., et al. “Synthesis and Properties of 8-nitro-7-alkylated Theophylline Derivatives.” J. Serb. Chem.. Soc., 1993, 58(7-8), pp. 499-505.
Van Muijlwijk-Koezen, J.E., et al. “synthesis and use of FSCPX, an Irreversible Adenosine A1 Antagonists, As a ‘Receptor Knock-Down’ Tool.” Bioorganic & Medicinal Chemistry Letters, 2001, 11, pp. 815-818.
ChemCats Database, Accession No. 2001:1002466.
ChemCats Database, Accession No. 2001:954502.
ChemCats Database, Accession No. 2001:950360.
ChemCats Database, Accession No. 2001:403692.
ChemCats Database, Accession No. 2001:115710.
ChemCats Database, Accession No. 2001:700909.
ChemCats Database, Accession No. 2001:481318.
ChemCats Database, Accession No. 2001:480523.
ChemCats Database, Accession No. 2001:477895.
ChemCats Database, Accession No. 2001:473970.
ChemCats Database, Accession No. 2001:403815.
ChemCats Database, Accession No. 2001:403693.
ChemCats Database, Accession No. 2001:403688.
ChemCats Database, Accession No. 2001:403681.
ChemCats Database, Accession No. 2001:294351.
ChemCats Database, Accession No. 2001:294343.
ChemCats Database, Accession No. 2001:294124.
ChemCats Database, Accession No. 2001:115711.
ChemCats Database, Accession No. 2001:1022442.
ChemCats Database, Accession No. 2001:1021391.
HCAPLUS Database, Accession No. 1998:100946.
HCAPLUS Database, Accession No. 1990:604407.
HCAPLUS Database, Accession No. 1987:50153.
HCAPLUS Database, Accession No. 2002:38476.
Registry Database, Registry No. 354133-04-3.
Registry Database, Registry No. 354132-96-0.
Registry Database, Registry No. 354132-95-9.
Registry Database, Registry No. 327098-61-3.
Registry Database, Registry No. 327097-83-6.
Registry Database, Registry No. 304878-88-4.
Registry Database, Registry No. 5429-50-5.
CAPLUS Database, Accession No. 1988:186421 (abstract only).
CAPLUS Database, Accession No. 1981:620045 (abstract only).
CAPLUS Database, Accession No. 1972:25126 (abstract only).
Boggs Sharon Davis
Collins Jon Loren
Fivush Adam
Stewart Eugene Lee
Willson Timothy Mark
Berch Mark L
Glaxo Group Limited
Young J. Scott
LandOfFree
Purine derivatives as liver X receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine derivatives as liver X receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine derivatives as liver X receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4073890